Prosecution Insights
Last updated: November 20, 2026
Application No. 17/339,425

GENE-EDITING SYSTEMS FOR EDITING A CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR (CFTR) GENE

Final Rejection §112
Filed
Jun 04, 2021
Priority
Dec 05, 2018 — provisional 62/775,637 +1 more
Examiner
JOHNSON, ALLISON MARIE
Art Unit
1638
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Vertex Pharmaceuticals Incorporated
OA Round
4 (Final)
40%
Grant Probability
At Risk
5-6
OA Rounds
0m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants only 40% of cases
40%
Career Allowance Rate
19 granted / 48 resolved
-20.4% vs TC avg
Strong +52% interview lift
Without
With
+52.1%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
38 currently pending
Career history
88
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
32.7%
-7.3% vs TC avg
§102
21.9%
-18.1% vs TC avg
§112
35.3%
-4.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 48 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1, 2, 5, 7, 9, 11, 12, 14, 19, 21, 24, 25, 28, 30, 32, 34, and 53 are pending. Claims 21, 24, 25, 28, 30, 32, and 53 are withdrawn. Claims 1, 2, 5, 7, 9, 11, 12, 14, 19, 34 are pending and under examination. Priority Applicant’s claim for the benefit of a prior-filed application provisional application 62/775,637 filed on 12/05/2018 and PCT/US2019/064718 filed 12/05/2019 under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, or 365(c) is acknowledged. Information Disclosure Statement The information disclosure statement filed 2/06/2026 is considered by the Examiner. Claim Rejections - 35 USC § 112(a) – Written Description - Maintained The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 2, 5, 7, 9, 11, 12, 14, 19, 34 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 1 recites a gene editing system comprising a first polynucleotide, comprising a nucleotide sequence encoding exons 11 to 27 of the CFTR gene and a pair of 5’ and 3’ homologous arm sequences (e.g., SEQ ID NO: 23 and SEQ ID NO: 24), a second polynucleotide comprising a second nucleotide sequence encoding an RNA-guided DNA endonuclease, and a third polynucleotide comprising a third nucleotide sequence encoding a guide RNA (gRNA) that directs cleavage at a target site (e.g., position 4262) of intron 10 of the CFTR gene. Claim 11 further limits the gRNA sequence (e.g., SEQ ID NO: 96). In analyzing whether the written description requirement is met for genus claims, it is first determined whether a representative number of species have been described by their complete structure. To provide adequate written description and evidence of possession of a claimed genus, the specification must provide sufficient distinguishing identifying characteristics of the genus. The factors to be considered include disclosure of complete or partial structure, physical and/or chemical properties, functional characteristics, structure/function correlation, methods of making the claimed product, or any combination thereof. The disclosure of a single species is rarely, if ever, sufficient to describe a broad genus, particularly when the specification fails to describe the features of that genus, even in passing. (see In re Shokal 113USPQ283(CCPA1957); Purdue Pharma L.P. vs Faulding Inc. 56 USPQ2nd 1481 (CAFC 2000). The court explained that “reading a claim in light of the specification, to thereby interpret limitations explicitly recited in the claim, is a quite different thing from ‘reading limitations of the specification into a claim,' to thereby narrow the scope of the claim by implicitly adding disclosed limitations which have no express basis in the claim.” The court found that applicant was advocating the latter, i.e., the impermissible importation of subject matter from the specification into the claim.). See also In re Morris, 127 F.3d 1048, 1054-55, 44 USPQ2d 1023, 1027-28 (Fed. Cir. 1997). The claims are broad for reciting specific 5’ and 3’ homology arms (e.g., SEQ ID NO: 23 and 24) with a gRNA sequence that directs cleavage at position 4262 of intron 10 of a CFTR gene. As written, the claims are generic to the target site of the gRNA (e.g., position 4262 of intron 10 of CFTR), with only claim 11 further limiting the gRNA to a specific sequence (e.g., SEQ ID NO: 96). The specification provides limited guidance on pairings of homology arm sequences and a gRNA sequence(s). While the working examples provide one specific pairing of homology arm sequences and gRNA sequences to target a specific position of intron 10, the specification does not provide further guidance on how to determine what homology arms and gRNA sequences can be used together, and what gRNA sequences, other than SEQ ID NO: 96, would be appropriate to use to target position 4262 of intron 10 of CFTR. For example, do the homology arms represented by SEQ ID NOs: 23 and 24 only work in combination with a gRNA comprising SEQ ID NO: 96? Can other gRNA sequences be used with SEQ ID NOs: 23 and 24 to target position 4262 successfully? Page 48 of the specification teaches a sgRNA represented by SEQ ID NO: 29 (which comprises SEQ ID NO: 96) paired with 5’ and 3’ homology arms represented by SEQ ID NOs: 23 and 24 to insert a nucleotide sequence comprising exons 11-27 of CFTR at position 4262 of intron 10 of CFTR. Figs. 7 and 8 show increased HDR rates and CFTR function when position 4262 was targeted with this gene editing system. No other gRNAs or homology arms were used to target position 4262 in the working examples. Additionally, Table 1 of the specification only teaches SEQ ID NO: 96 being used to target position 4262 during indel screenings of gRNAs. The art recognizes the importance of the specificity of gRNA and homology arm sequences in gene-editing. info.abmgood.com/crispr-cas9-introduction is considered relevant art for providing an overview of CRISPR Cas9 technology. In homology directed repair (HDR), a DNA repair template that has a high degree of homology to the sequence immediately upstream and downstream (i.e., homology arms) of the intended editing site is introduced into the cell along with the appropriate gRNA and Cas9 nuclease. In the presence of this suitable template, the less error-prone HDR mechanism can faithfully make the desired changes to the Cas9 induced DSB site through recombination, allowing for more precise repair mechanisms in cells compared to NHEJ (“The homology Directed Repair (HDR) with Cas9 Nuclease”; Figure 4). Bak R.O., Dever D.P., Porteus M.H. CRISPR/Cas9 genome editing in human hematopoietic stem cells. Nat. Protoc. 2018;13:358–376. is considered relevant prior art for teaching CRISPR/Cas9 editing via homologous recombination in human hematopoietic stem cells. Bak et al. outlines key steps for identifying and characterizing a highly active locus specific sgRNA for targeted gene editing, which is key to achieving optimal homologous recombination (HR) frequencies. Routinely, four to eight sgRNAs candidates are screened based on the frequency of insertions and deletions using tracking of INDELs by decomposition (TIDE) analysis. Once an sgRNA has been confirmed, a homologous donor template to introduce a desired genomic change is designed and cloned into an AAV vector plasmid. In general, the CRISPR cut site (between base pairs 17 and 18 of the 20-nt complementary sequence of the sgRNA) should ideally be located as close to the intended genomic change as possible. Bak et al. also found that the further the homology arms are from the break site, the lower the HR efficiencies, and that if the HR process is to integrate DNA exactly at the double-strand break, the arms should be split at the CRISPR cut site (Fig. 1a). (pg. 361-362, “Experimental design” – sgRNA design and Donor design). Devkota, Sushil. "The road less traveled: strategies to enhance the frequency of homology-directed repair (HDR) for increased efficiency of CRISPR/Cas-mediated transgenesis." BMB reports 51.9 (2018): 437. is considered relevant prior art for teaching strategies to enhance homology-directed repair (HDR) for increased efficiency of CRISPR/Cas-mediated transgenesis. Devkota explains that at its core, the CRISPR/Cas system consists of an endonuclease whose DNA-targeting specificity is dictated by a short-guide RNA. One of the strategies discussed by Devkota to improve HDR efficiency is physically positioning donor DNA near the cleavage site. By supplying the donor DNA with homology-arms around the target site, a researcher can hope that the donor DNA externally supplied is used as a repair template (pg. 440, col 2, last para). Several recent studies have positioned donor DNA near the target site instead of randomly floating them in the nucleoplasm, and this strategy has been successful to increase the HDR efficiency. In summary, the art teaches the necessity in a gene editing systems comprising an RNA-guided DNA endonuclease of specific gRNA sequences and homology arm sequences used together in order to successfully target a specific position for editing. Thus, in light of the implied generic nature of the claims and the lack of further guidance in the specification and prior art of what gRNA sequence(s) would be appropriate to use with the 5’ and 3’ homology arm sequences recited (SEQ ID NO: 23 and 24) in order to target position 4262 of intron 10 of the CFTR gene, the Artisan would not have understood Applicant to have been in possession of the invention as claimed. Thus, for the reasons outlined above, it is concluded that the claims do not meet the requirements for written description under 35 U.S.C. 112, first paragraph. Response to Arguments Applicant's arguments filed 08/06/2026 have been fully considered but they are not persuasive. Regarding the 112a Written Description rejection, the Applicant argues: “a person of ordinary skill in the art would understand from the disclosure provided in the application as filed that position 4262 (as well as the other CFTR positions recited in claim 1) corresponds to the cut site produced by the RNA-guided DNA endonuclease (e.g., SaCas9). For example, the brief description of FIG. 2 provided on page 5, lines 26-32 of the specification as filed recites that FIG. 2 "is a diagram showing candidate cut sites identified from a 120 saCas9 gRNA Indel screen in electroporated lung progenitor cells." A person of ordinary skill in the art would therefore understand from the specification and figures as filed that claim 1 refers to targeting specific cut sites within the CFTR gene.” This argument is not persuasive because the art teaches that to target a specific site for cutting, a specific gRNA and homology arms pair are necessary (see Written Description rejection above). It is understood that claim 1 refers to targeting specific cute sites, such as position 4262, in the CFTR gene. However, this does not remedy the broadness of the claims in regard to the generic recitation of gRNA sequence(s) used/gRNA sequences + homology arm sequence pairings. The Applicant also argues: “a person of ordinary skill in the art would have knowledge of how to design a gRNA to cut at position 4262 and that would be suitable for use with the homology arms of SEQ ID NOs: 23 and 24, for example, a gRNA slightly longer or shorter or with modified nucleotides versus the exemplary gRNA of SEQ ID NO: 96. The specification teaches that the homology arms are adjacent to the cut site. See e.g., Example 1, page 35, lines 4-5, which states that the AAV donor construct contained: "500 nucleotide long left and right homology arms relative to the gRNA cut site." (Emphasis added)” This argument is not found to be persuasive because the Applicant fails to distinctly point out or provide evidence that an artisan would have knowledge of how to design a gRNA to cut at position 4262 that would be suitable for use with homology arms SEQ ID NOs: 23 and 24 without undue experimentation. For example, what is considered “slightly” longer or shorter? What nucleotides can be modified and still maintain function? The Examiner notes that although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993) (e.g., the claims are not limited to the teachings of the specification, such as pairs of gRNA sequences and homology arms taught in the specification). Conclusion No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALLISON M JOHNSON whose telephone number is (703)756-1396. The examiner can normally be reached Monday-Friday 9am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Tracy Vivlemore can be reached on (571) 272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ALLISON MARIE JOHNSON/Examiner, Art Unit 1638 /ROBERT M KELLY/Primary Examiner, Art Unit 1638
Read full office action

Prosecution Timeline

Show 3 earlier events
May 12, 2025
Response Filed
Jun 03, 2025
Response Filed
Nov 06, 2025
Final Rejection mailed — §112
Feb 06, 2026
Request for Continued Examination
Feb 09, 2026
Response after Non-Final Action
May 07, 2026
Non-Final Rejection mailed — §112
Aug 06, 2026
Response Filed
Oct 29, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12751974
COMPOSITION FOR USE IN TREATING DYSTROPHIC EPIDERMOLYSIS BULLOSA
5y 2m to grant Granted Oct 06, 2026
Patent 12703873
ARTIFICIAL EXPRESSION CONSTRUCTS FOR SELECTIVELY MODULATING GENE EXPRESSION IN EXCITATORY CORTICAL NEURONS
5y 3m to grant Granted Aug 11, 2026
Patent 12698489
METHODS, COMPOSITIONS AND COMPONENTS FOR CRISPR-CAS9 EDITING OF TGFBR2 IN T CELLS FOR IMMUNOTHERAPY
6y 3m to grant Granted Aug 04, 2026
Patent 12692512
METHODS AND COMPOSITIONS FOR TREATING GLYCOGEN STORAGE DISEASES
5y 1m to grant Granted Jul 28, 2026
Patent 12577539
CELLS FOR ENHANCED PRODUCTION OF ADENO-ASSOCIATED VIRUS
4y 4m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
40%
Grant Probability
92%
With Interview (+52.1%)
4y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 48 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month